Methods of Treatment and Outcome for Ovarian Germ Cell Tumors

  • Assem Ahmed ElbrashyEmail author
  • Amr Kamal
  • Mohamed Ibrahim Fahim
Original Article


Ovarian germ cell tumors account for about 15–20% of all ovarian tumors. They occur mainly in girls, adolescents, and young adults. This study aims to assess the different clinico-pathological factors of ovarian germ cell tumors, treatment methods, and outcome. This is a retrospective observational cohort study including 54 cases with OGCTs which were studied from the period between January 2013 and December 2016. The study was performed at National Cancer Institute (NCI)–Cairo University, Egypt. All cases had cytoreductive surgery in the form of unilateral salpingo-oophorectomy in 42 cases and total abdominal hysterectomy in 12 cases. Complete cytoreduction was achieved in 46 cases while 8 cases had residual disease after surgery. Adjuvant chemotherapy was given in 26 cases (stage II, III, and IV malignant OGCTs). The main treatment of ovarian germ cell tumors is complete cytoreductive surgery which can be achieved in many cases with unilateral salpingo-oophorectomy. Adjuvant chemotherapy is highly recommended in case of malignant ovarian germ cell tumors.


Germ cell ovarian tumors (GCOT) Cytoreductive surgery (CRS) Management 


Funding Information

The study was supported by NCI–Cairo University.

Compliance with Ethical Standards

NCI played no role in the study design, data collection, data analysis, or manuscript writing. All authors read and approved the final manuscript.

The study was approved by the ethical committee of NCI. Clinical data were collected from hospital medical records and investigations’ reports, recorded in a standard database form, and evaluated and analyzed by the authors. For this type of study (retrospective study), formal consent is not required.

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Mangili G, Sigismondi C, Lorusso D, Cormio G, Candiani M, Scarfone G, Mascilini F, Gadducci A, Mosconi AM, Scollo P, Cassani C, Pignata S, Ferrandina G (2017) The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. Ann Oncol 28(2):333–338. Google Scholar
  2. 2.
    Maltaris T, Boehm D, Dittrich R et al (2006) Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol 103:1109CrossRefGoogle Scholar
  3. 3.
    Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, Williams SD, Gynecologic Oncology Group (2007) Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J ClinOncol 25:2792–2797CrossRefGoogle Scholar
  4. 4.
    Lai CH, Chang TC, Hsueh S et al (2005) Outcome and prognostic factors in ovarian germ cell malignancies. GynecolOncol 96:784Google Scholar
  5. 5.
    Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL (2014) Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children’s Oncology Group. J Clin Oncol 32(5):465–470. CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2019

Authors and Affiliations

  • Assem Ahmed Elbrashy
    • 1
    Email author
  • Amr Kamal
    • 1
  • Mohamed Ibrahim Fahim
    • 1
  1. 1.Surgical Oncology DepartmentNational Cancer Institute-Cairo UniversityFoum El-KhaligEgypt

Personalised recommendations